Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAXIMISE: Secukinumab in Axial Psoriatic Arthritis
NCT02721966Phase 3Completed
- Sponsor
- Novartis
- Start
- Oct 2016
- Primary completion
- Jun 2019
- Modality
- Monoclonal Antibodies
- Countries
- 18
01
Overview
A Phase 3 trial of secukinumab in axial psoriatic arthritis (axPsA), sponsored by Novartis. Started Oct 2016; status: completed.
02
Drugs
secukinumab
03
Conditions
axial psoriatic arthritis (axPsA)
Beyond the preview
Go deeper on NCT02721966.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02721966.